found that the compressive strength of BP-loaded CPC was similar to that of cancellous bone, while the setting time of CPC was prolonged [9, 10] . While CPC has a long history as a substitute to repair bone fractures, its insufficient mechanical strength in poorly vascularized regions always raises some concerns [11] . In our previous research, we attempted to deliver risedronate (RA), a third generation BP, from calcium silicate cement (CSC) [3] , because CSC is more bioactive and has a higher compressive strength than CPC [12] . However, due to drawbacks of CSC (e.g. low setting rate and highly basic environment in situ) [12, 13] , we developed calcium phosphate silicate cement (CPSC) as a better substitute to repair bone fractures [14] . It was found that CPSC was more biocompatible than CSC and provided better osseointegration than CPC. However, there are no studies attempting to deliver BP with CPSC.
In the present study, we designed a local RA delivery system with CPSC. Effects of this drug delivery system (RA-CPSC) on CPSC material properties as well as in vivo effects in osteoporotic rabbits were investigated. Most importantly, we examined the osteogenic and anti-osteoporotic effects of RA-CPSC at the systemic (whole body) and local (close to implant) levels.
Materials and methods

Materials preparation and characterization
Materials preparation
Calcium silicate powder (50 wt% of Ca 2 SiO 4 and 50 wt% of Ca 3 SiO 5 ) was provided by Innovative BioCeramix (Vancouver, Canada). To yield RA-CPSC, 10 wt% of monocalcium phosphate (MCP, Ca(H 2 PO 4 ) 2 , Fisher Chemical, USA) and 0.5 wt% or 1.0 wt% of risedronate (RA, Beta Pharma, Branford, USA) were added into calcium silicate powder and homogeneously mixed in a mortar to yield RA-CPSC. These samples are referred to as CPSC (RA-free), 0.5% RA-CPSC and 1.0% RA-CPSC, respectively. Deionized water was added to CPSC or RA-CPSC powders at 0.5 ml g −1 to achieve the hydration and setting of the cement.
Material characterization
Cement pastes were molded into 17 mm × 2 mm (diameter × height) and 6 mm × 12 mm polystyrene cylinders for the setting time and compressive strength tests, respectively. The setting time was determined in accordance with the ASTM standard test method (ASTM ID: C191-08, Standard Test Methods for Time Setting of Hydraulic Cement by Vicat Needle). Only the final setting time was recorded (n = 4). The compressive strengths were determined on an Instron3369 (High Wycombe, Buckinghamshire, UK) test machine, equipped with a 50 kN load cell, at a crosshead speed of 2.54 mm min −1 (n = 8).The samples were set in a 37 °C and 100% relative humidity incubator for 3 and 7 d, respectively. A statistical analysis was conducted to compare the compressive strengths of the same sample between 3 d and 7 d hydration.
An x-ray diffractometer (XRD, MultiFlex, Rigaku, Japan, with Cu-Kα at 40 kV and 20 mA source), with a shutter and standard sample holder, was used to characterize the crystal structure of the cements. In order to quantitatively analyze the crystalline structures of the cements, Rietveld refinement was performed on ball-milled samples to reduce their particle size to <10 μm.
Step-scan was carried out over a two-theta range of 10°-100° with 0.05 degree/step and 5s/step. The scan results were analyzed using the Inorganic Crystal Structure Database and diffraction patterns were refined with HighScore Plus (Version 3.0, PANalytical, Netherlands). Silicon was added as the reference for calculations in the Rietveld refinement analysis. A scanning electron microscope (SEM, Hitachi S-3000N, Hitachi Co., Japan), equipped with an EDX analyzer, was used to examine the samples' microstructures after 7 d of hydration.
Micro-computed tomography (μCT, MicroCT 100, SCANCO Medical AG, Brüttisellen, Switzerland) was used to visualize and calculate the porosity (>5 μm) in 7 d cement samples. In addition, porosity was also measured by the gas-sorption pore size analyzer (Autosorb-1 series; Quantachrome Instruments, Boynton Beach, USA) and compared with data obtained from μCT. In the evaluation of porosity by nitrogen gas sorption, samples were outgassed in glass tubes at 25 °C for 24 h before testing isothermally at the same temperature. Fourier transform infrared (FTIR; PE100 series, PerkinElmer, Waltham, MA, USA.) analyses were used to detect hydroxyapatite interference (between 4000 cm −1 and 400 cm −1 ) with the Si-O-Si bond in 7 d hydrated samples. Cement samples were ground into powders and evaluated by FTIR in the attenuated total reflection (ATR) mode.
In vitro tests 2.2.1. MTT cell viability assay of osteoblast cells
Osteoblast cells were isolated from calvaria of neonatal (<2 d old) Sprague-Dawley rats by an enzymatic digestive process [15] , and only those between the second and fourth passages were used in our study. The extract method was used to evaluate cell viability by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and extracts were prepared by putting cement samples in 10 ml phosphate buffer solution (PBS) at 37 °C for 1 and 3 d. Subsequently, extracts were sterile filtered with a 0.22 μm filter and stored in the refrigerator for future use. The evaluation of the cytotoxicity of RA-CPSC on osteoblast cells was conducted in accordance with ISO 10993-5 standards using the extract method. Extracts were diluted to 50% (v/v) with Dulbecco's Modified Eagle's Medium (DMEM, Hyclone, USA) with 10% heatinactivated fetal bovine serum (FBS, Hyclone, USA) to form extract medium. Each well of a 96-well plate was seeded with 5 × 10 3 osteoblast cells in 200 μl of the extract medium and incubated at 37 °C in a humidified atmosphere containing 5% CO 2 for 3 d prior to test. An MTT assay (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide, Sigma, USA) was used to evaluate osteoblast cell viability as previously described [3] . The viability was calculated as the absorbance at 570 nm (OD 570 ) of the sample divided by the OD 570 of CPSC.
Gene expression analysis on RT-PCR
Osteoblast-specific genes, alkaline phosphatase (ALP), osteoprotegerin (OPG), runt-related transcription factor 2 (Runx2) and transforming growth factor-β (TGF-β), were evaluated in this study, while the β-actin gene served as the housekeeping gene. Total RNA from cells cultured in bone cement extracts for 3 
Cell cycle analysis
Cells cultured in bone cement extracts for 1 d were collected by centrifugation, washed twice with cold PBS, and then fixed in 75% ethanol at 4 °C overnight. Cells were then collected, washed with cold PBS, and stained with500 μl of PBS (50 μg ml −1 of propidium iodide and 100 μg ml −1 of RNeasy A). Subsequently, cells were incubated at 4 °C for 30 min and analyzed on a flow cytometer (BD FACS CantoII, BD Biosciences, San Jose, USA). Results were analyzed by ModFit LT 3.6 (Verity Software House, Topsham, ME, USA, n = 3).
Statistical analysis
The software SPSS ® Statistics 19.0 (SPSS Inc., Chicago, IL, USA) was used in the statistical analyses of our data.
After testing the homogeneity of variance, one-way ANOVA was performed to compare values among individual groups.
In vivo study 2.3.1. Animal model
Thirty female New Zealand rabbits (~6 months, 1.5-2.1 kg) were randomly divided into 3 groups in this study and referred to as the sham group (control), CPSC (RA-free, 10% MCP), and 0.5% RA-CPSC (0.5% RA, 10% MCP), respectively. The animal study was approved by the animal welfare committee of Safety Evaluation Centre in Shenyang Research Institute of Chemical Industry (SRICI, permit No.:K002). All animals were bilaterally ovariectomized after one-week acclimation period and osteoporosis was induced by injecting methylprednisolone (1 mg d −1 kg −1 , SoluMedrol, Pfizer, USA) for 28 d [16] . Subsequently, the epiphysis on the tibia from each right hind leg was either implanted with bone cement or perforated as the sham control. The detailed implantation procedure is given in the supplement (stacks.iop.org/BMM/11/045002/ mmedia). Two endpoints were designed in this study, 8 weeks (n = 5) and 10 weeks (n = 5).
Biomarker analyses for model validation and anti-resorptive effects
During the period of osteoporotic model creation, a 2 ml blood sample (n = 30, biological replicates) from each rabbit was collected from the ear artery at a two-week interval after the beginning of glucocorticoid injection. Samples were allowed to clot for 30 min in blood tubes (Vacutainer, BD Biosciences, San Jose, CA, USA) at room temperature and centrifuged at 3000 rpm for another 10 min for the separation of blood serum. Serums were pooled together and then divided into 2 ml aliquots for storage. The tartrate resistant acid phosphatase5b isoform (TRACP-5b) in serum was measured by an enzyme-linked immunosorbent assay (ELISA) kit (Quidel Corporation, San Diego, CA, USA) to validate the osteoporotic model (technical replicates, n = 6). Starting at the 4th week after implantation, 2 ml blood samples (n = 10 for week 4, 6 and 8, and n = 5 for week 10 only, biological replicates) were collected from each rabbit and treated in the same way as described above. Serum samples collected from the same group were pooled and then divided into 2 ml aliquots for storage. Serum levels of TRACP-5b, pyridinoline crosslinks (PYD), deoxypyridinoline crosslinks (DPD), hydroxyproline (OHP), N-terminal telopeptide (NTX) and C-terminal telopeptide (CTX) were detected by ELISA kits (Quidel Corporation, San Diego, CA, USA) (technical replicates, n = 6).
Radiographic and histological analysis
At the pre-determined endpoints of 8 and 10 weeks, rabbits were transferred to a local hospital for clinical radiographic examination and then sacrificed to perform the histological studies. The rabbits were anesthetized by intravenous injection of pentobarbital sodium (2%, 1 ml kg −1 ) to induce obfuscation. X-ray (Kodak DirectView DR7500, Carestream Health, USA) images were taken at 50 kVp and 160 mA for 10 ms and CT scans were conducted on the CT scanner (Discovery CT750 HD, GE Healthcare, USA, resolution = 0.625 mm) at 100 kV and 20 mA (n = 5). Semi-quantitative analyses were attempted based upon x-ray images and details are given in the supplementary material. Subsequently, the animals were sacrificed by CO 2 inhalation. Epiphyses on the right tibiae were excised and surrounding soft tissues were removed. Specimens were then fixed in 10% neutral buffered formalin, dehydrated in graded series of ethanol, decalcified in acid and embedded in paraffin wax. Thereafter, three longitudinal ground-sections of 5 μm were prepared for each half. All sections were stained with hematoxylin-eosin and examined by light microscopy. Parameters, including signs of inflammation, encapsulation, presence of osteoblast cells and new bone formation were observed.
PCR array analysis
At the endpoint of the 10th week, total RNA was isolated from peri-implant bone fragments prior to the treatment of histological preparation and analyzed by PCR arrays to study the RA-CPSC effects on osteogenesis. To effectively isolate total RNA from bone, fragments (10 mg),with 5 ml trizol (QIAzol, Qiagen, Valencia, CA, USA) added, were milled thoroughly in liquid nitrogen. After allowing the mixtures to stand for 10 min, 1 ml chloroform was added and shaken rigorously. Subsequently, mixtures were left undisturbed for another 15 min and centrifuged at 4 °C for 15 min. Total RNA was isolated from the supernatants by the RNeasy Plus Mini Kit (Qiagen) and pooled (biological replicates, n = 5). Expression levels of 84 osteogenesis-related genes were analyzed by PCR arrays (RT 2 Profiler PCR Array osteogenesis, Qiagen, n = 4 for technical replicates). For details, see the supplementary material.
Results and discussion
Material characterizations
The setting time was significantly increased at 1.0% RA and the compressive strengths were more compromised In CPSC and 0.5% RA-CPSC samples, the 3 d strengths were similar to the 7 d strengths (12-13 MPa); however, in 1.0% RA-CPSC samples, the compressive strength after 3 d setting was significantly lower than that after 7 d setting, implying that RA retarding effects on CPSC setting was time-dependent. Regardless of RA concentration, RA-CPSC demonstrated sufficient mechanical strength as compared to the cancellous bone [9] . Material properties of CPSC are primarily attributed to the hydration of calcium silicate in CPSC to form calcium silicate hydrate (CSH) gel. The reductions in compressive strength and the increase in setting time are likely the result of RA interfering with the hydration of calcium silicate [3] . In 1.0% RA-CPSC samples, the initial hydration reaction is impeded by RA and hydration proceeds slowly, resulting in higher compressive strengths after 7 d than 3 d. In the quantitative analysis of the crystalline phase (figures 2(a) and (b)), it was found that the CSH gel formation was lower with increasing RA content in CPSC, possibly because of the RA interference with calcium silicate hydration. This reduction in CSH gel formation well explains the reduction in compressive strength with RA. In addition, MCP could react with calcium hydroxide to form apatite and reduce the pH of setting CPSC [14] . The dissolution of apatite in vivo is an abundant source of Ca can promote the bone healing process [14] . FTIR results ( figure 2(c) ) demonstrated that peaks in the region between 1400 cm −1 and 1500 cm −1 could be attributed to the formation of carbonates during calcium silicate hydration [17] . Furthermore, these peaks were more distinguishable in the 1.0% RA samples 
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than RA-free CPSC. Reasons for this observation might be that calcium hydroxide formed during hydration strongly absorbs carbon dioxide from the atmos phere to form carbonates in amorphous form, which cannot be resolved by XRD. Together, the quantitative analyses of XRD patterns and FTIR results indicate that the amorphous phase was highest in 1.0% RA-CPSC samples. In addition, peaks between 800 cm −1 and 1200 cm −1 could be clearly assigned to Si-O-Si bonds. No significant difference in porosity was found between the bone cements with or without RA, although μCT seemed to show that CPSC had slightly larger pores ( figure 3(d) ). The porosity analysis by μCT revealed that the overall porosity fraction of pores >5 μm in size was highest for CPSC (about 5%), and similar (about 3-4%) for the RA-CPSCs. The use of the gas sorption method ( figure 3(d) ) confirmed this trend, which was also observed by other researchers [10] . MicroCT measures cement porosity based upon the difference of thresholding values between cement particles and air and has a measurement resolution of 5 μm. A significant portion of CPSC pores are in size smaller than 5 μm [18] , which cannot be resolved by μCT; however, the nitrogen gas sorption method is capable of detecting pores with much smaller sizes [19] . Therefore, the gas sorption method yielded a larger porosity values than the μCT method in our study. SEM micrographs (figures 4(a)-(c)) indicated that, with increasing RA content, the size of crystals was smaller and the microstructures seemed more closely packed as a result of RA interference during hydration [3] . RA impedes the growth of CSH gel crystals and creates more amorphous phase. These small crystals and amorphous phases seem to fill in some large pores, resulting in an overall smaller porosity.
In vitro biocompatibility
An MTT assay ( figure 5(a) ) confirmed that RA incorporation in CPSC (up to 1.0%) showed no cytotoxic effects on osteoblast cells, agreeing with our previous finding where we incorporated RA into a CSC [3] . In the current study, we also compared the DNA tetraploid amount ( figure 5(b) ) between osteoblast cell samples treated by CPSC, 0.5% RA-CPSC and 1.0% RA-CPSC and prove that RA-added CPSC had the same proliferating effects on osteoblast cells as RAfree CPSC. This proliferating effect may be attributed to abundant calcium (Ca 2+ ) ions found in the CPSC extract solutions [20] .
In order to further evaluate in vitro biocompatibility, cell proliferation and differentiation were determined by expressions of four commonly used osteoblast-specific genes. As shown in figures 6(a)-(c), ALP, OPG and runx2 expressions in 0.5% RA-CPSC were significantly higher than those in either CPSC or 1.0% RA-CPSC. The only down-regulated gene was TGF-β ( figure 6(d) ), which decreased significantly with increasing RA content. As a mediator, runx2 plays an important role in osteoblast differentiation [20] , and its expression was found to be significantly higher in 0.5% RA-CPSC than in CPSC or 1.0% RA-CPSC. This may be because RA up-regulating effects on runx2 expression are time and concentration-dependent [21] . The transcription factor, runx2, regulates the expression of ALP, which is responsible for osteoblast differentiation [20] , and the up-regulation of ALP gene in 0.5% RA-CPSC compared to the other two groups well agreed with the runx2 expressions.
Since OPG inhibits osteoclastogenesis [22] , the upregulation of OPG expression in RA-added samples proves that RA contributes anti-osteoclastogenesis effects. In both OPG and ALP expressions, it was found that 1.0% RA-CPSC expressions were lower than 0.5% RA-CPSC, proving that RA had concentration-dependent effects on these gene expressions [22, 23] . TGF-β is responsible for osteoblast proliferation [20] , and its expression is down-regulated with increasing RA concentration in CPSC, possibly because TGF-β expression is highly depending on the into extracts [3, 24] . Our attempts to analyze the RA in vitro release from CPSC in PBS up to 6 months failed likely because the release concentration was below the resolution of the chromatographic method.
Systemic anti-osteoporotic effects
Our biomarker study showed that RA significantly reduced the prevalence of osteoporosis but insignificantly prevented bone resorption as compared to the RA-free CPSC. The relation of biomarkers tested in our study is given in figure 7 (a). Serum TRACP-5b level results ( figure 7(b) ) strongly imply that osteoclast activities in all rabbits were significantly elevated due to the treatment of glucocorticoid injection as well as the bilateral ovariectomy [25] . As shown in figure 7(b) , the TRACP-5b serum level increased with treatment time and the serum level after 4 weeks was significantly (p < 0.05) higher than the baseline level on the first day after injection. The serum TRACP-5b levels (figure 7(c)) further increased in all three groups from week 4 to 10. However, its level was the lowest in the 0.5% RA-CPSC group, implying that RA-added CPSC had positive effects in treating osteoporosis by reducing both osteoclast activity and number of osteoclast cells [26] . CTX, NTX, DPD, PYD and OHP levels are bone turnover indicators and were significantly (p < 0.05) decreased in CPSC and 0.5% RA-CPSC as compared to the sham control group (figures 7(d)-(h)) [27] , implying that both CPSC and 0.5% RA-CPSC have positive effects in preventing bone resorption and promoting bone growth. However, in these biomarker studies, results between CPSC and 0.5% RA-CPSC were not significantly different, making RA-added CPSC effects on preventing bone resorption as compared to RA-free CPSC inconclusive. This may be attributed to the low amount of RA that is locally released from the CPSC [28] , which cannot be sufficiently delivered within the whole body to be significantly effective.
Local osteogenic effects
Clinical x-ray and CT images show that there was more trabecular bone formation after 10 weeks of implantation of 0.5% RA-CPSC than CPSC. Figure 8 (a) shows x-ray radiographs after 8 and 10 weeks of implantation for each treatment group. 
Biomed. Mater. 11 (2016) 045002
Newly formed trabecular bone was indifferent between CPSC and 0.5% RA-CPSC groups after 8 weeks of implantation. After 10 weeks, there seemed to be more newly formed trabecular bone in the 0.5% RA-CPSC group than in CPSC, although this is a non-quantitative observation. CT scans ( figure 8(b) ) also indicated that there was more bone formation (green color) around cement (red color) in 0.5% RA-CPSC than CPSC after 10 weeks. A semi-quantitative analysis ( figure 8(c) ) shows a trend towards more trabecular bone formation in 0.5% RA-CPSC than in CPSC. After 8 weeks of implantation, new bone formation was only slightly higher in 0.5% RA-CPSC than in CPSC. After 10 weeks of implantation, however, more bone formation in the 0.5% RA-CPSC group was found. Based upon semiquantitative analyses, the resorption of new bone was not significantly lower in 0.5% RA-CPSC than CPSC, implying that long term studies (>6 months) and better analytical methods (e.g. μCT) may be needed to observe significant results of RA on the prevention of bone resorption.
Histological observations showed better bone restoration and healing in the 0.5% RA-CPSC group than the CPSC alone group (figure 9). In the control group ( figure 9(a) ), there was no newly formed bone in the vicinity of the perforation. Instead, a band of proliferative connective tissue was observed. The perforation formed an elliptical structure, which consisted of proliferative connective tissue, granulation tissue and fibrous tissue composed of collagen fibers, fibroblasts, and fiber cells. In addition, adipose tissue, neutrophils and osteoclasts were also present. In the CPSC group, basic bone restoration was evident in the form of a thin layer of lamellar bone ( figure 9(b) ). In addition, osteoblasts were present, which were absent in the control. In the 0.5% RA-CPSC group ( figure 9(c) ), a larger amount of newly formed bone shaped in long strips or irregular sheets was observed. These results confirmed that the number of osteoclast cells was reduced in 0.5% RA-CPSC versus CPSC after 10 weeks, implying that the release of RA successfully suppressed the osteoclast survival and activities by inducing osteoclast apoptosis [29] . The presence of granulation tissues indicated that the healing process started and was better in 0.5% RA-CPSC and CPSC than the control group because CPSC seems to enhance the fractural restoration [30] . The above studies proved that, as a RA local delivery system, 0.5% RA-CPSC can provide superior biological (longer-term) stability and osseointegration than CPSC. In addition, the differences in preventing bone resorption between local and systemic effects may be attributed to the fact that the release of RA from CPSC was localized to the implant [28] . (c) Up-regulated genes in CPSC and 0.5% RA-CPSC groups compared to the sham control after 10 weeks of implantation (n = 4) (p < 0.005). Two common genes up-regulated by both CPSC and 0.5% RA-CPSC are indicated by asterisks ( * A further indication of effects by 0.5% RA-CPSC on bone regeneration comes from the analysis of RNA isolated from peri-implant bone fragments after sacrifice of the animals. The comparison of 84 osteogenesis-related gene expressions between CPSC (and 0.5% RA-CPSC) and the sham control were analyzed by PCR arrays (figure 10). A significantly higher number of up-regulated genes was found in the 0.5% RA-CPSC group than in the CPSC group (14 versus 2, p < 0.005 and threshold = 6). PCR array studies demonstrated that 0.5% RA-CPSC was better in promoting local periimplant bone formation than CPSC alone. Twelve more genes were up-regulated in the 0.5% RA-CPSC group versus the CPSC group after 10 weeks of implantation, strongly implying that RA improved the osseointegration between CPSC and bone tissue [31] . The upregulation of the two common genes LOC100009177 (collagen, type III, alpha 1) and SPP1 (secreted phosphoprotein 1) by both CPSC and 0.5% RA-CPSC, may be attributed to the release of Ca ions during CPSC degradation, encouraging local bone formation [32] . Based upon the difference between systemic and local results, it can be concluded that RA is likely taken up by peri-implant bone minerals, resulting in significant local effects, but insignificant systemic effects.
Conclusions
CPSC as a drug delivery system for RA was evaluated for the first time. It was found that both setting time and compressive strength of CPSC were affected by the higher concentration (1 wt%) of RA because of the formation of RA-calcium complexes impeding the cement hydration. Cell viability assays showed that the RA-CPSC system was biocompatible and realtime PCR and flow cytometry revealed that RA-CPSC promoted osteoblast proliferation and differentiation.
In the osteoporotic animal model, RA-added CPSC significantly reduced the prevalence of osteoporosis as confirmed by a biomarker study. In addition, local radiographic, histological and PCR array studies demonstrated that RA-added CPSC increased osseointegration by promoting local bone formation and preventing peri-implant bone resorption. Since no significant RA systemic effects on preventing bone resorption were observed in this study, it might be interesting to in the future increase the quantity of RA loading in CPSC, potentially with help of polymer encapsulation, and to observe the systemic effects of RA-CPSC on the prevention of bone resorption.
